Capital Investment Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Investment Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-363	Closed	-$203K	–	713
2020 Q3	$203K	Buy	363 +2	+0.6%	+$1.21K	0.04%	356
2020 Q2	$225K	Sell	361 -100	-22%	-$56.8K	0.05%	293
2020 Q1	$225K	Buy	+461	New	+$190K	0.05%	272
2019 Q4	–	Sell	-211	Closed	-$59K	–	1090
2019 Q3	$59K	Hold	211	–	–	0.02%	522
2019 Q2	$63K	Buy	211 +200	+1,818%	+$66.6K	0.02%	504
2019 Q1	$5K	Hold	11	–	–	﹤0.01%	981
2018 Q4	$4K	Buy	+11	New	+$4.03K	﹤0.01%	976

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Investment Advisory Services's REGN Position: Q4 2020 in Review

Capital Investment Advisory Services sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 363 shares — an estimated $203K sold.

Capital Investment Advisory Services first reported a position in REGN in Q4 2018 and held it in 7 quarters. The position peaked at $225K in Q2 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

Capital Investment Advisory Services reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Capital Investment Advisory Services sold 363 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $203K.
Capital Investment Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 7 quarters.
Capital Investment Advisory Services's Regeneron Pharmaceuticals position peaked at $225K in Q2 2020.
903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Capital Investment Advisory Services's 13F filing for Q4 2020, filed 25 Jan 2021.